Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection (Q41155364)

27 September 2017

1 reference

title

Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection (English)

1 reference

27 September 2017

1 reference

1 reference

1 reference

A P Lea

1 reference

27 September 2017

D Faulds

series ordinal

1 reference

27 September 2017

publication date

1 May 1996

1 reference

27 September 2017

1 reference

27 September 2017

1 reference

27 September 2017

1 reference

27 September 2017

page(s)

846-864

1 reference

Dose proportionality of stavudine in HIV seropositive asymptomatic subjects: application to bioequivalence assessment of various capsule formulations

27 September 2017

cites work

1 reference

12 December 2020

Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture

1 reference

12 December 2020

Synthesis and anti-HIV evaluation of D4T and D4T 5'-monophosphate prodrugs

1 reference

12 December 2020

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex

1 reference

12 December 2020

Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy

1 reference

12 December 2020

Differential inhibitory effects of several pyrimidine 2',3'-dideoxynucleoside 5'-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases

1 reference

12 December 2020

Evaluation of the Combination Effect of Different Antiviral Compounds against HIV in Vitro

1 reference

12 December 2020

Immunopathogenesis of HIV infection

1 reference

12 December 2020

Tetrazolium-based plaque assay for HIV-1 and HIV-2, and its use in the evaluation of antiviral compounds

1 reference

12 December 2020

Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus

1 reference

12 December 2020

The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides

1 reference

12 December 2020

Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial

1 reference

12 December 2020

Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age.

1 reference

12 December 2020

Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group

1 reference

12 December 2020

Metabolism and DNA interaction of 2',3'-didehydro-2',3'-dideoxythymidine in human bone marrow cells

1 reference

12 December 2020

Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex

1 reference

12 December 2020

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group

1 reference

12 December 2020

Comparative studies of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) with other pyrimidine nucleoside analogues

1 reference

12 December 2020

The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain

1 reference

12 December 2020

1 reference

12 December 2020

Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity

1 reference

12 December 2020

Pharmacokinetic Optimisation of Antiretroviral Therapy in Patients with HIV Infection

1 reference

12 December 2020

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

12 December 2020

Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection

1 reference

12 December 2020

Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection

1 reference

12 December 2020

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

1 reference

12 December 2020

Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.

1 reference

12 December 2020

Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders

1 reference

12 December 2020

A bend in the road--implications of ACTG 175 and Delta trials

1 reference

12 December 2020

Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases

1 reference

12 December 2020

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides

1 reference

12 December 2020

Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates

1 reference

12 December 2020

2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial

1 reference

12 December 2020

Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro

1 reference

12 December 2020

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

12 December 2020

Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus

1 reference

12 December 2020

Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients

1 reference

12 December 2020

In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase

1 reference

12 December 2020

Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

1 reference

12 December 2020

Pathogenesis of human immunodeficiency virus infection

1 reference

12 December 2020

A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection

1 reference

12 December 2020

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

12 December 2020

Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides

1 reference

12 December 2020

Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.

1 reference

12 December 2020

Statistics from the World Health Organization

1 reference

12 December 2020

Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.

1 reference

12 December 2020

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

12 December 2020

Comparative embryonic cytotoxicity of antiretroviral nucleosides

1 reference

12 December 2020

Effects of 2',3'-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis

1 reference

12 December 2020

Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5'-triphosphate in comparison to cellular DNA polymerases alpha and beta

1 reference

12 December 2020

3'-Deoxythymidin-2'-ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion

1 reference

12 December 2020

1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent

1 reference

12 December 2020

Antiviral therapy in human immunodeficiency virus infections. Current status (Part I).

1 reference

12 December 2020

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

1 reference

12 December 2020

2',3'-Dideoxythymidine permeation of the human erythrocyte membrane by nonfacilitated diffusion

1 reference

12 December 2020

Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus

1 reference

12 December 2020

5-Chloro-substituted derivatives of 2', 3'-didehydro-2',3'-dideoxyuridine, 3'-fluoro-2',3'-dideoxyuridine and 3'-azido-2',3'-dideoxyuridine as anti-HIV agents

1 reference

12 December 2020

Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T).

1 reference

12 December 2020

Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells

1 reference

12 December 2020

Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

1 reference

12 December 2020

Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)

1 reference

12 December 2020

Guidelines for the design and conduct of AIDS clinical trials. AIDS Clinical Trials Group

1 reference

12 December 2020

Controversies in anti-retroviral therapy of adults

1 reference

12 December 2020

Anti-HIV-1 activity of antiviral compounds, as quantitated by a focal immunoassay in CD4+ HeLa cells and a plaque assay in MT-4 cells

1 reference

12 December 2020

Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections

1 reference

12 December 2020

Pharmacologic studies of nucleosides active against the human immunodeficiency virus

1 reference

12 December 2020

1 reference

12 December 2020

In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virus

1 reference

12 December 2020

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study

1 reference

12 December 2020

Fidelity of HIV-1 reverse transcriptase

1 reference

12 December 2020

The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta

1 reference

12 December 2020

In vivo maternal-fetal pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in pigtailed macaques (Macaca nemestrina).

1 reference

12 December 2020

Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.

1 reference

12 December 2020

HIV resistance to reverse transcriptase inhibitors

1 reference

12 December 2020

HIV inhibitors targeted at the reverse transcriptase

1 reference

12 December 2020

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group

1 reference

12 December 2020

Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus

1 reference

12 December 2020

Mitochondrial toxicity of antiviral drugs

1 reference

12 December 2020

Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene.

1 reference

12 December 2020

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds

1 reference

12 December 2020

Design and implementation of the stavudine parallel-track program

1 reference

12 December 2020

10.2165/00003495-199651050-00009

Identifiers

DOI

1 reference

Dimensions Publication ID

27 September 2017

1046433807

0 references

1 reference